Novartis AG (NYSE:NVS) traded with a cut of -1.52 points or -1.93% at $77.42 per share. As per the last available information, the stock aggregated $20.96 million in upticks and $17.71 million in downticks, keeping the net money flow capped at $3.25 million. The up/down ratio was found to be 1.18. For the week, the shares have seen a change of -4.36% in the share price.A block trade of $1.26 million in upticks and $0 million in downticks also took place during the day. The up/down ratio for the block stood at 0. The net money flow for this transaction was $1.26 million.
Currently the company Insiders own 0.01% of Novartis AG shares according to the proxy statements. Institutional Investors own 9.96% of Novartis AG shares.
Novartis AG (NYSE:NVS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.61 points or 2.04% at $77.33 with 2,201,460 shares getting traded. Post opening the session at $77.74, the shares hit an intraday low of $77.29 and an intraday high of $78.26 and the price was in this range throughout the day. The company has a market cap of $184,144 million and the number of outstanding shares have been calculated to be 2,381,276,500 shares. The 52-week high of Novartis AG (NYSE:NVS) is $106.84 and the 52-week low is $69.895.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Morgan Stanley, downgrades their rating on the shares of Novartis AG (NYSE:NVS). Morgan Stanley has a Underperform rating on the shares. Previously, the analysts had a Equal-weight rating on the shares. The rating by the firm was issued on April 12, 2016.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.